Scholarlink

<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing global health concern. However, the molecular mechanisms underlying its onset and progression remain incompletely understood. This study aimed to investigate the molecular mechanism by which the transcription factor CCAAT/enhancer-binding protein α (C/EBPα) regulates hepatic lipid accumulation through the miR-335-5p–mediated PRKAA2/AMPK signaling pathway. MASLD models were established both in high-fat diet (HFD)-fed mice and in free fatty acid (FFA)-treated hepatocytes. Gene expression, lipid accumulation, and related signaling pathways were analyzed using quantitative RT–PCR, Western blotting, Oil Red O staining, dual-luciferase reporter assays, and rescue experiments. We identified a novel regulatory axis in which C/EBPα transcriptionally activates miR-335-5p, leading to suppression of PRKAA2, the catalytic subunit of AMPKα2, and subsequent inhibition of AMPK signaling. This cascade promotes the expression of lipogenic genes and enhances hepatic lipid deposition. Inhibition of either C/EBPα or miR-335-5p restored PRKAA2/AMPK activity, reduced intracellular triglyceride and cholesterol levels, and alleviated hepatic steatosis in both cellular and murine models. Conversely, PRKAA2 silencing reproduced the lipogenic phenotype, while its overexpression rescued miR-335-5p-induced lipid accumulation. Our findings reveal a previously unrecognized C/EBPα/miR-335-5p/PRKAA2 axis that drives hepatic lipogenesis and steatosis in MASLD. Targeting this signaling pathway—by inhibiting C/EBPα or miR-335-5p, or activating PRKAA2/AMPK—may provide a promising therapeutic strategy for MASLD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel C/EBPα–miR-335-5p–PRKAA2 regulatory axis drives hepatic lipid accumulation in MASLD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Xiying Zeng,
  • Yajing Xu,
  • Sufang You,
  • Honghong Duan,
  • Qingyan Cai,
  • Huibin Huang

摘要

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing global health concern. However, the molecular mechanisms underlying its onset and progression remain incompletely understood. This study aimed to investigate the molecular mechanism by which the transcription factor CCAAT/enhancer-binding protein α (C/EBPα) regulates hepatic lipid accumulation through the miR-335-5p–mediated PRKAA2/AMPK signaling pathway. MASLD models were established both in high-fat diet (HFD)-fed mice and in free fatty acid (FFA)-treated hepatocytes. Gene expression, lipid accumulation, and related signaling pathways were analyzed using quantitative RT–PCR, Western blotting, Oil Red O staining, dual-luciferase reporter assays, and rescue experiments. We identified a novel regulatory axis in which C/EBPα transcriptionally activates miR-335-5p, leading to suppression of PRKAA2, the catalytic subunit of AMPKα2, and subsequent inhibition of AMPK signaling. This cascade promotes the expression of lipogenic genes and enhances hepatic lipid deposition. Inhibition of either C/EBPα or miR-335-5p restored PRKAA2/AMPK activity, reduced intracellular triglyceride and cholesterol levels, and alleviated hepatic steatosis in both cellular and murine models. Conversely, PRKAA2 silencing reproduced the lipogenic phenotype, while its overexpression rescued miR-335-5p-induced lipid accumulation. Our findings reveal a previously unrecognized C/EBPα/miR-335-5p/PRKAA2 axis that drives hepatic lipogenesis and steatosis in MASLD. Targeting this signaling pathway—by inhibiting C/EBPα or miR-335-5p, or activating PRKAA2/AMPK—may provide a promising therapeutic strategy for MASLD.